Predicting DNA methylation level across human tissues

Baoshan Ma,Elissa H. Wilker,Saffron A. G. Willis-Owen,Hyang-Min Byun,Kenny C. C. Wong,Valeria Motta,Andrea A. Baccarelli,Joel Schwartz,William O. C. M. Cookson,Kamal Khabbaz,Murray A. Mittleman,Miriam F. Moffatt,Liming Liang
DOI: https://doi.org/10.1093/nar/gkt1380
IF: 14.9
2014-01-20
Nucleic Acids Research
Abstract:Differences in methylation across tissues are critical to cell differentiation and are key to understanding the role of epigenetics in complex diseases. In this investigation, we found that locus-specific methylation differences between tissues are highly consistent across individuals. We developed a novel statistical model to predict locus-specific methylation in target tissue based on methylation in surrogate tissue. The method was evaluated in publicly available data and in two studies using the latest IlluminaBeadChips: a childhood asthma study with methylation measured in both peripheral blood leukocytes (PBL) and lymphoblastoid cell lines; and a study of postoperative atrial fibrillation with methylation in PBL, atrium and artery. We found that our method can greatly improve accuracy of cross-tissue prediction at CpG sites that are variable in the target tissue [R(2) increases from 0.38 (original R(2) between tissues) to 0.89 for PBL-to-artery prediction; from 0.39 to 0.95 for PBL-to-atrium; and from 0.81 to 0.98 for lymphoblastoid cell line-to-PBL based on cross-validation, and confirmed using cross-study prediction]. An extended model with multiple CpGs further improved performance. Our results suggest that large-scale epidemiology studies using easy-to-access surrogate tissues (e.g. blood) could be recalibrated to improve understanding of epigenetics in hard-to-access tissues (e.g. atrium) and might enable non-invasive disease screening using epigenetic profiles.
biochemistry & molecular biology
What problem does this paper attempt to address?